This is the ยฎrst case report of rhabdomyolysis without neuroleptic malignant syndrome induced by additional treatment of risperidone. The manifestations of this side eect were symptoms of myalgia, muscle weakness and redcoloured urine with ยฎndings of markedly elevated levels of creatine kinase and m
Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome
โ Scribed by Pang-Yen Liu; Pei-Chuan Wu; Chun-Yen Chen; Yi-Chyan Chen
- Book ID
- 113635872
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 113 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0163-8343
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Neuroleptic malignant syndrome (NMS) is a rare and sometimes fatal adverse reaction to neuroleptic drugs. Atypical antipsychotic agents, such as risperidone, are thought to be less likely to cause N M S because of their phamacologiical profile. This is a case report of NMS associated with risperidon
Successful use of risperidone after neuroleptic malignant syndrome (NMS): a 1-year follow-up Neuroleptic malignant syndrome (NMS) is a rare and an acute life-threatening reaction that can occur in patients on neuroleptic medication. Few authors have addressed the issue of re-challenge in previous NM